Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US
Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo
Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and
The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,
Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. Consequently researchers are developing
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of
Evolution Global Talent Attraction recently signed a contract to provide human capital to newly formed company QuantiHealth in China. QuantiHealth was founded by Zhao Bowen, who was named as one
Evolution Global Talent Attraction’s latest market research report looks at the capacity and content of biopharmaceutical production in Europe, the Middle East and Africa. Rather than publish a lengthy report,
Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic
Thermo Fisher Scientific have signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals, for £256 million (approximately $405 million USD) in cash. Alfa Aesar’s
